Search DIAN Tissue Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 1 - 10 of 80

Investigator:

Anna Krichevsky

Title:

MicroRNAs neuroprotection for AD and other neurodegenerative diseases

Date of Request:

02/01/2021

Aim 1:

Test the efficacy of selected miRNA modulators in major disease-associated genetic backgrounds in iNeurons.

Investigator:

Oscar Harari

Title:

Metabolomic and lipidomics changes in ADAD

Date of Request:

08/13/2020

Aim 1:

Determine metabolite signatures of ADAD

Aim 2:

Identify locus-metabolite and lipids associations via Metabolite genome-wide association studies (M-GWAS).

Investigator:

Charlotte Teunissen

Title:

Measurement of glial fibrillary acidic protein (GFAP) levels in blood for evaluation of astrocyte reaction in Alzheimer disease.

Date of Request:

08/14/2020

Aim 1:

Determine trajectory of GFAP over the ADAD disease course in relation to amyloid

Investigator:

Teunissen

Title:

Add-on DIAN project 3 Novel mechanisms: pilot OLINK proteomics in left-over CSF aliquots

Date of Request:

08/14/2020

Aim 1:

Study which OLINK proteins (signature) are discriminative between ADAD and controls

Aim 2:

Compare with sporadi AD

Aim 3:

Compare with Mass Spec in ADAD

Investigator:

Ronald Hawley

Title:

TEST BIO SUBMISSION

Date of Request:

08/07/2020

Aim 1:

test the form

Aim 2:

test the form 2

Aim 3:

test the form 3

Aim 4:

test the form 4

Investigator:

Laura Ibanez

Title:

Plasma cell-free RNA as non-invasive biomarker for neurodegeneration

Date of Request:

08/05/2020

Aim 1:

Validate genomic models for disease pathology in Autosomal Dominant Alzheimer

Aim 2:

Develop a specific predictive model for ADAD

Investigator:

Randall Bateman

Title:

Identification and validation of novel AD biomarkers for clinical development of Eisai AD pipelines

Date of Request:

07/02/2020

Aim 1:

To profile of CSF MTBR-tau isoforms which can be captured by E2814 across all DIAD stages using CSF samples from DIAN-observation cohort.

Investigator:

1) Dr. Alison M. Goate, 2) Dr. Sarah M. Neuner

Title:

Defining the role of microglia in Alzheimer’s disease risk and resilience

Date of Request:

04/01/2020

Aim 1:

Aim 1: Investigate the effect of high-risk or protective amyloid precursor protein (APP) mutations on microglia cell function.

Investigator:

Jérôme Braudeau

Title:

Optimization of a blood diagnosis of the silent phase of Alzheimer's disease

Date of Request:

03/11/2020

Aim 1:

Confirm the performance of a diagnostic algorithm developed on European plasma samples.

Aim 2:

Improve the algorithm by learning on human plasma samples of more varied genetic origin and environmental background.

Aim 3:

Improve the algorithm by learning on human plasma samples collected longer before the diagnosis of Alzheimer's disease.

Investigator:

Henrietta Nielsen

Title:

Apolipoprotein E isoform levels and their relevance to the development of AD pathology

Date of Request:

03/11/2020

Aim 1:

By use of mass-spectrometry assess and compare the individual apolipoprotein E isoform levels in plasma and CSF from familial AD patients versus controls

Aim 2:

To investigate whether fluid levels of apolipoprotein E are related to the estimated year of disease onset, CSF and imaging AD biomarkers in familial AD patients

Aim 3:

To elucidate a potential correlation between plasma apolipoprotein E levels and previously assessed CSF alpha-synuclein levels whereof the latter appeared related to amyloid-beta deposition and symptom onset